Market Intelligence Center  Oct 16  Comment 
United Therapeutics (UTHR) presents a trading opportunity that offers a 9.05% return in just 127 days. A covered call on United Therapeutics at the $120.00 level expiring on Feb. '15 offers an assigned return rate of 9.05% or 26.01% annualized....
Yahoo  Sep 26  Comment 
The CEO of biotech firm United Therapeutics discusses the outlook for biotech and need for public-private partnerships.
Forbes  Sep 25  Comment 
Investors eyeing a purchase of United Therapeutics Corp (NASD: UTHR) shares, but tentative about paying the going market price of $134.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
Yahoo  Sep 25  Comment 
Martine Rothblatt is the highest paid female exeuctive in America. She made $38 million last year as the CEO of United Therapeutics; a $6 billion biotech firm she founded to find a treatment for pulmonary hypertension after her daughter was...
SeekingAlpha  Sep 19  Comment 
By Sharon di Stefano: Pulmonary arterial hypertension (PAH), a progressive and life threatening illness that regrettably takes a back seat to cardiovascular disease where research is concerned, is incurable and fatal. Characterized by high blood...
Benzinga  Sep 17  Comment 
Apogee Enterprises (NASDAQ: APOG) shares jumped 8.67% to reach a new 52-week high of $39.56 after the company reported adjusted FQ2 earnings of $0.35 per share on revenue of $231.9 million. However, analysts were estimating earnings of $0.34 per...
Benzinga  Sep 17  Comment 
Axsome Therapeutics, Inc. today announced that Roger Jeffs, Ph.D., Mark Saad, and Mark Coleman, M.D. will join its Board of Directors. Dr. Jeffs is President and Chief Operating Officer (COO) of United Therapeutics Corporation (Nasdaq: UTHR), a...
StreetInsider.com  Sep 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Pluristem+Therapeutics+%28PSTI%29+Reports+Initial+Dosing+of+PLX-PAD+Phase+I+%28UTHR%29/9811922.html for the full story.
Motley Fool  Aug 29  Comment 
United Therapeutics stock is among today's top gainers after it announces a favorable legal ruling regarding its best-selling drug, Remodulin.
StreetInsider.com  Aug 29  Comment 
52-Week High: Digital Ally (Nasdaq: DGLY) $19.55. Digital Ally continuing to see strong gains Friday as on-officer camera speculation heats up. The stock has moved over 360 percent higher since August 18th and closed 36 percent better on...

You may also be interested in articles related to United Therapeutics (UTHR):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki